Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

2006 • 3,172 citations

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

1996 • 2,410 citations

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1998 • 2,049 citations

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

1993 • 1,908 citations

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

1995 • 1,903 citations

Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

2006 • 1,289 citations

Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis

2005 • 1,060 citations

Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab

2005 • 1,033 citations

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

2002 • 937 citations

Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis

1998 • 931 citations

Interferon beta‐lb in the treatment of multiple sclerosis

1995 • 899 citations

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

2008 • 868 citations

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS

1999 • 728 citations

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

2001 • 697 citations

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

2006 • 660 citations

European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

2001 • 595 citations

PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS

2001 • 563 citations

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

2006 • 552 citations

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS

2001 • 471 citations

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.

1997 • 425 citations

Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-?1a in relapsing-remitting multiple sclerosis

1999 • 384 citations

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

2003 • 370 citations

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b

1996 • 361 citations

Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis

1998 • 334 citations

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

2007 • 323 citations

The incidence and significance of anti-natalizumab antibodies

2007 • 322 citations

Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients

2006 • 315 citations

Baseline MRI predicts future attacks and disability in clinically isolated syndromes

2006 • 284 citations

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

2004 • 254 citations

Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis

1993 • 252 citations

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

2008 • 248 citations

Measures in the first year of therapy predict the response to interferon β in MS

2009 • 234 citations

Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosis

2005 • 228 citations

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

1998 • 220 citations

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

2009 • 217 citations

Defining interferon β response status in multiple sclerosis patients

2004 • 216 citations

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approach

2009 • 213 citations

TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis

2003 • 205 citations

Neutralizing antibodies and efficacy of interferon β-1a

2005 • 202 citations

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

2005 • 196 citations

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients

2000 • 180 citations

Interferon β-1a in MS

2005 • 180 citations

Transcription-Based Prediction of Response to IFNβ Using Supervised Computational Methods

2004 • 175 citations

Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients

2003 • 173 citations

Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis

2008 • 171 citations

Expression profiling identifies responder and non‐responder phenotypes to interferon‐β in multiple sclerosis

2003 • 170 citations

Interferon-β increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity

2008 • 155 citations

Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article].

2001 • 138 citations

Optimizing the association between disability and biological markers in MS

2001 • 137 citations

Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a

2003 • 136 citations

Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action

2005 • 135 citations

Interferon β‐1a for early multiple sclerosis: CHAMPS trial subgroup analyses

2002 • 133 citations

Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

2002 • 125 citations

Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis

2001 • 121 citations

Predictors of long–term clinical response to interferon beta therapy in relapsing multiple sclerosis

2005 • 120 citations

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

2004 • 120 citations

HLA-DRB1∗0401 and HLA-DRB1∗0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis

2008 • 113 citations

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

2008 • 113 citations

Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients

2008 • 112 citations

Treatment Optimization in Multiple Sclerosis

2004 • 106 citations

Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis

1997 • 105 citations

The clinical impact of interferon beta antibodies in relapsing-remitting MS

2004 • 93 citations

Predictive markers for response to interferon therapy in patients with multiple sclerosis

2008 • 91 citations

MxA Gene Expression Analysis as an Interferon-β Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity

2003 • 88 citations

IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response

2005 • 87 citations

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

2004 • 86 citations

A comparative study of the relative bioavailability of different interferon beta preparations

2000 • 86 citations

Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicity

2005 • 86 citations

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS

2009 • 83 citations

Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis

2005 • 83 citations

A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta

2005 • 82 citations

Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis

2003 • 79 citations

The effect of interferon β-1b on quantities derived from MT MRI in secondary progressive MS

2003 • 79 citations

Neutralizing antibodies reduce MxA protein induction in interferon- beta-1a-treated MS patients

2002 • 78 citations

Pharmacogenomics of responsiveness to interferon IFN-β treatment in multiple sclerosis: A genetic screen of 100 type I interferon-inducible genes

2005 • 78 citations

Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

2007 • 76 citations

Neutralizing antibodies against IFN- in multiple sclerosis: antagonization of IFN- mediated suppression of MMPs

2004 • 68 citations

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

2001 • 62 citations

Neutralizing antibodies hamper IFNβ bioactivity and treatment effect on MRI in patients with MS

2006 • 61 citations

MRI activity and neutralising antibody as predictors of response to interferon treatment in multiple sclerosis

2007 • 59 citations

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

2007 • 55 citations

Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis

1998 • 50 citations

A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting

2006 • 50 citations

Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives

2008 • 49 citations

Multiplex analysis of expression of three IFNβ-induced genes in antibody-positive MS patients

2006 • 49 citations

Effects of interferon-β on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-β treatment in patients with multiple sclerosis

2007 • 48 citations

IL‐10 promoter haplotype influence on interferon treatment response in multiple sclerosis

2005 • 46 citations

Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice

2007 • 46 citations

Relapsing-Remitting Multiple Sclerosis

2000 • 46 citations

Magnetization transfer ratio in new MS lesions before and during therapy with IFNβ-1a

2000 • 44 citations

Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis

2007 • 43 citations

Using measurements of neutralizing antibodies: the challenge of IFN-? therapy

2007 • 41 citations

Reduced effectiveness of long-term interferon-β treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study

2007 • 41 citations

Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon β-1a: analysis of the PRISMS study

2008 • 40 citations

Expression and regulation of IFNα/β receptor in IFNβ-treated patients with multiple sclerosis

2008 • 38 citations

Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS

2005 • 35 citations

TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-β treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response

2007 • 34 citations

Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience

2005 • 34 citations

Genomic effects of once-weekly, intramuscular interferon-β1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients

2008 • 33 citations

Switching algorithms: from one immunomodulatory agent to another

2008 • 31 citations

Combination Therapy for Multiple Sclerosis

2004 • 27 citations

Translation towards personalized medicine in Multiple Sclerosis

2008 • 26 citations

Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies

2007 • 23 citations

Potential for Interferon Beta–Induced Serum Antibodies in Multiple Sclerosis to Inhibit Endogenous Interferon-Regulated Chemokine/Cytokine Responses Within the Central Nervous System

2006 • 23 citations

Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders

1999 • 23 citations

Interleukin-10 and Interleukin-12 Modulation in Patients with Relapsing-Remitting Multiple Sclerosis on Therapy with Interferon-beta 1a: Differences in Responders and Non Responders

2008 • 23 citations

Avonex Combination Trial in relapsing—remitting MS: rationale, design and baseline data

2008 • 22 citations

Saliva soluble HLA as a potential marker of response to interferon-β1a in multiple sclerosis: A preliminary study

2007 • 21 citations

Heterogeneity in Response to Interferon Beta in Patients With Multiple Sclerosis

2008 • 21 citations

Chemokine receptor CCR5 in interferon-treated multiple sclerosis

2007 • 18 citations

MRI relapses have significant pathologic and clinical implications in multiple sclerosis

2007 • 17 citations

Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?

2008 • 17 citations

CD8+ T cell activation correlates with disease activity in clinically isolated syndromes and is regulated by interferon-β treatment

2006 • 17 citations

Combination therapy in multiple sclerosis

2007 • 16 citations

Neutralizing antibodies against interferon beta: fluctuation is modest and titre dependent

2008 • 15 citations

Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging

2005 • 15 citations

Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of Interferon beta-1b in patients with Secondary Progressive Multiple Sclerosis

2005 • 15 citations

Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis

2008 • 15 citations

Combination therapy

2006 • 13 citations

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

2009 • 12 citations

Switching to Second-Line Therapies in Interferon-Beta-Treated Relapsing-Remitting Multiple Sclerosis Patients

2009 • 12 citations

Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria

2008 • 11 citations

Multiple sclerosis: Relating MxA transcription to anti-interferon-β-neutralizing antibodies

2007 • 8 citations

Combination Therapy in Multiple Sclerosis

2006 • 6 citations

Combination therapy for the treatment of multiple sclerosis: challenges and opportunities

2007 • 6 citations

Could cytokines levels or adhesion molecules expression be predictor of IFN-β treatment response in multiple sclerosis patients?

2008 • 1 citations

Deleted Work

1955 • 0 citations